Table 2. Molecular response and clinical... | American Society of Hematology

Table 2.

Molecular response and clinical outcome after GO

	Results of qualitative RT-PCR for PML-RARα*
Patient no.	1st cycle	2nd cycle	3rd cycle	No. GO cycles received	Relapse/type	Duration of molecular remission, mos.	Successive therapies	Outcome
1	ND	Negative	Negative	3	No	31+	—	Alive in MR
2	Negative	Negative	Negative	3	No	14+	—	Alive in MR
3	Positive	Positive	—	2	Yes/morphologic	NE	MITOX, MITOX†	Alive in MR
4	Negative	Negative	Negative	3	Yes/molecular	13	GO†/MITOX + ARA-C	Alive in MR
5	Negative	Negative	Negative	3	Yes/morphologic	6	MITOX + ARA-C	Died of disease progression
6	ND	Negative	Negative	3	No	7+	—	Alive in MR
7	ND	ND	—	2	Yes/morphologic	NE	—	Died of disease progression
8	Negative	ND	Negative	3	Yes/molecular	7	MITOX + ARA-C	Alive in MR
9	ND	Negative	Negative	3	Yes/molecular	8	GO‡	Alive in MR
10	ND	Negative	Negative	3	No	19+	—	Alive in MR
11	Negative	—	—	1	Yes/molecular	6	DLI	Alive in MR
12	ND	ND	Negative	3	No	12+	—	Alive in MR
13	ND	ND	Negative	3	No	19+	DLI	Alive in MR
14	ND	Positive	Negative	3	No	15+	—	Alive in MR
15	ND	Negative	Negative	3	Yes/molecular	15	—	Alive in MR
16	Negative	Negative	Negative	3	Yes/morphologic	3	ATO	Died of disease progression

	Results of qualitative RT-PCR for PML-RARα*
Patient no.	1st cycle	2nd cycle	3rd cycle	No. GO cycles received	Relapse/type	Duration of molecular remission, mos.	Successive therapies	Outcome
1	ND	Negative	Negative	3	No	31+	—	Alive in MR
2	Negative	Negative	Negative	3	No	14+	—	Alive in MR
3	Positive	Positive	—	2	Yes/morphologic	NE	MITOX, MITOX†	Alive in MR
4	Negative	Negative	Negative	3	Yes/molecular	13	GO†/MITOX + ARA-C	Alive in MR
5	Negative	Negative	Negative	3	Yes/morphologic	6	MITOX + ARA-C	Died of disease progression
6	ND	Negative	Negative	3	No	7+	—	Alive in MR
7	ND	ND	—	2	Yes/morphologic	NE	—	Died of disease progression
8	Negative	ND	Negative	3	Yes/molecular	7	MITOX + ARA-C	Alive in MR
9	ND	Negative	Negative	3	Yes/molecular	8	GO‡	Alive in MR
10	ND	Negative	Negative	3	No	19+	—	Alive in MR
11	Negative	—	—	1	Yes/molecular	6	DLI	Alive in MR
12	ND	ND	Negative	3	No	12+	—	Alive in MR
13	ND	ND	Negative	3	No	19+	DLI	Alive in MR
14	ND	Positive	Negative	3	No	15+	—	Alive in MR
15	ND	Negative	Negative	3	Yes/molecular	15	—	Alive in MR
16	Negative	Negative	Negative	3	Yes/morphologic	3	ATO	Died of disease progression

ND indicates not done; MR, molecular remision; NE, not evaluable; ATO, arsenic trioxide; DLI, donor lymphocyte infusion; and —, patient did not receive this treatment. See Table 1 footnote for other abbreviations.

In 4 cases, the material collected after the second GO dose was insufficient for RT-PCR analysis.

†

Patient received 3 additional GO doses.

‡

Patient received 4 additional GO doses.

View Large

This Feature Is Available To Subscribers Only